$BAYA
Bayview Acquisition Corp

2024 Q2 Form 10-Q Financial Statement

#000149315224019972 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $121.5K $158.9K $14.61K
YoY Change 5018.71%
Operating Profit -$121.5K -$158.9K
YoY Change 5018.71%
Interest Expense $713.8K $754.3K $107.1K
YoY Change
% of Operating Profit
Other Income/Expense, Net $713.8K $754.3K
YoY Change
Pretax Income $592.3K $595.4K $92.44K
YoY Change
Income Tax
% Of Pretax Income
Net Earnings $592.3K $595.4K $92.44K
YoY Change -19274.75%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.08 $0.08 $0.01
COMMON SHARES
Basic Shares Outstanding 7.733M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $331.9K $582.3K
YoY Change
Cash & Equivalents $225.5K $331.9K $582.3K
Short-Term Investments
Other Short-Term Assets $132.5K $60.18M
YoY Change
Inventory
Prepaid Expenses $108.7K $132.5K $72.01K
Receivables
Other Receivables $21.20K $199.7K
Total Short-Term Assets $355.4K $664.0K $654.3K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $60.87M $29.68K
YoY Change
Total Long-Term Assets $61.58M $60.87M $60.14M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $355.4K $664.0K $654.3K
Total Long-Term Assets $61.58M $60.87M $60.14M
Total Assets $61.93M $61.54M $60.79M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses $265.6K $466.1K $303.8K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $265.6K $466.1K $313.8K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.100M $2.100M
YoY Change
Total Long-Term Liabilities $2.100M $2.100M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $265.6K $466.1K $313.8K
Total Long-Term Liabilities $2.100M $2.100M
Total Liabilities $2.366M $2.566M $2.414M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$2.010M -$1.889M -$1.730M
YoY Change
Common Stock $173.00 $173.00 $196.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.010M -$1.889M -$1.730M
YoY Change
Total Liabilities & Shareholders Equity $61.93M $61.54M $60.79M
YoY Change

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income $592.3K $595.4K $92.44K
YoY Change -19274.75%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$106.3K -$250.4K -$4.410K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$60.00M
YoY Change
Cash From Investing Activities -$60.00M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 60.59M
YoY Change
NET CHANGE
Cash From Operating Activities -106.3K -$250.4K -4.410K
Cash From Investing Activities -60.00M
Cash From Financing Activities 60.59M
Net Change In Cash -106.3K -$250.4K 582.3K
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$106.3K -$250.4K -$4.410K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41890
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
BAYVIEW ACQUISITION CORP
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
E9
CY2024Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
13310 usd
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001969475
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
usd
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2024Q1 us-gaap Stock Granted During Period Value Sharebased Compensation Forfeited
StockGrantedDuringPeriodValueSharebasedCompensationForfeited
usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
usd
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
usd
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
usd
CY2024Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2023Q1 BAYA Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Income Earned On Trust Account
SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionIncomeEarnedOnTrustAccount
usd
CY2024Q1 BAYA Deferred Offering Costs Paid By Sponsors In Exchange For Issuance Of Ordinary Shares
DeferredOfferingCostsPaidBySponsorsInExchangeForIssuanceOfOrdinaryShares
usd
CY2024Q1 BAYA Deferred Offering Costs Paid By Related Party
DeferredOfferingCostsPaidByRelatedParty
usd
CY2024Q1 BAYA Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
usd
CY2024Q1 BAYA Prepaid Expenses Included In Due To Related Party
PrepaidExpensesIncludedInDueToRelatedParty
usd
CY2023Q1 BAYA Interest Earned On Investment Held In Trust Account
InterestEarnedOnInvestmentHeldInTrustAccount
usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
420 Lexington Ave, Suite 2446
CY2024Q1 us-gaap Cash
Cash
331872 usd
CY2024Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
199677 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
132500 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
664049 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
29677 usd
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
60861367 usd
CY2024Q1 us-gaap Assets
Assets
61538726 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
466055 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
466055 usd
CY2024Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2100000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
2566055 usd
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6000000 shares
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6000000 shares
CY2024Q1 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.14
CY2023Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.02
CY2024Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
60861367 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1732500 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1732500 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1957500 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1957500 shares
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6000000 shares
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6000000 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
173 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1888869 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1888696 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61538726 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
158936 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-158936 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3105 usd
CY2024Q1 us-gaap Investment Income Net
InvestmentIncomeNet
754312 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
754312 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
595376 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3105 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
225000 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1729760 usd
CY2024Q1 BAYA Stock Issued During Period Value Subsequent Measurement Of Common Stock Subject To Possible Redemption Interest Earned On Trust Account
StockIssuedDuringPeriodValueSubsequentMeasurementOfCommonStockSubjectToPossibleRedemptionInterestEarnedOnTrustAccount
-754312 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
595376 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-1888696 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
25100 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3105 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3105 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
21995 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
225000 shares
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
595376 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3105 usd
CY2024Q1 us-gaap Investment Income Net
InvestmentIncomeNet
754312 usd
CY2024Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
35563 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
87386 usd
CY2024Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-10000 usd
CY2024Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
29677 usd
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
3105 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-250436 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-250436 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
582308 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
331872 usd
CY2024Q1 BAYA Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption Income Earned On Trust Account
SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemptionIncomeEarnedOnTrustAccount
754312 usd
CY2023Q1 BAYA Deferred Offering Costs Paid By Sponsors In Exchange For Issuance Of Ordinary Shares
DeferredOfferingCostsPaidBySponsorsInExchangeForIssuanceOfOrdinaryShares
25100 usd
CY2023Q1 BAYA Deferred Offering Costs Paid By Related Party
DeferredOfferingCostsPaidByRelatedParty
113305 usd
CY2023Q1 BAYA Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
15995 usd
CY2023Q1 BAYA Prepaid Expenses Included In Due To Related Party
PrepaidExpensesIncludedInDueToRelatedParty
1429 usd
CY2024Q1 BAYA Percentage Of Outstanding Voting Securities
PercentageOfOutstandingVotingSecurities
1 pure
CY2024Q1 us-gaap Cash
Cash
331872 usd
CY2024Q1 BAYA Working Capital
WorkingCapital
197994 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_ztW2aVjILevl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zKSHE0Vsa3U4">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the financial statement in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
331872 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
582308 usd
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
60861367 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
60107055 usd
CY2024Q1 us-gaap Investment Income Net
InvestmentIncomeNet
754312 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
540000 shares
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.50
CY2024Q1 BAYA Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePricePercentage
1.15 pure
CY2024Q1 BAYA Number Of Optionsand Units Shares
NumberOfOptionsandUnitsShares
540000 shares
CY2024Q1 BAYA Number Of Options And Units Ordinary Shares
NumberOfOptionsAndUnitsOrdinaryShares
540000 shares
CY2024Q1 BAYA Number Of Options And Units Rights To Purchase Ordinary Shares
NumberOfOptionsAndUnitsRightsToPurchaseOrdinaryShares
54000 shares
CY2024Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
170000 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
595376 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3105 usd
CY2024Q1 BAYA Interest Earned On Investment Held In Trust Account
InterestEarnedOnInvestmentHeldInTrustAccount
754312 usd
CY2024Q1 BAYA Net Loss Including Accretion Of Common Stock To Redemption Value
NetLossIncludingAccretionOfCommonStockToRedemptionValue
-158936 usd
CY2023Q1 BAYA Net Loss Including Accretion Of Common Stock To Redemption Value
NetLossIncludingAccretionOfCommonStockToRedemptionValue
-3105 usd
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_842_eus-gaap--ConcentrationRiskCreditRisk_zHQIPxEvshsh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_z7edy8qNGqM5">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_90E_eus-gaap--CashFDICInsuredAmount_iI_c20240331_za8kEzYgBKEa" title="Cash, FDIC insured amount">250,000</span>. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2024Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2022 BAYA Stock Issued During Period Value Proceeds From Sales Of Public Units
StockIssuedDuringPeriodValueProceedsFromSalesOfPublicUnits
60000000 usd
CY2022 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
-2460000 usd
CY2022 BAYA Temporary Equity Offering Costs
TemporaryEquityOfferingCosts
4163327 usd
CY2022 BAYA Accretion Of Carrying Value To Redemption Value
AccretionOfCarryingValueToRedemptionValue
6623327 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
60000000 usd
CY2023 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
107055 usd
CY2023Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
60107055 usd
CY2024Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
754312 usd
CY2024Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
60861367 usd
CY2023Q4 BAYA Cash Underwriting Discount Per Unit
CashUnderwritingDiscountPerUnit
0.20
CY2023Q4 BAYA Cash Underwriting Discount
CashUnderwritingDiscount
1200000 usd
CY2023Q4 BAYA Cash Underwriting Discount
CashUnderwritingDiscount
1200000 usd
CY2024Q1 BAYA Deferred Commission Per Unit
DeferredCommissionPerUnit
0.35
CY2024Q1 BAYA Deferred Commission
DeferredCommission
2100000 usd
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100 usd
CY2024Q1 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
170000 usd
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
voting and other rights and preferences as may be determined from time to time by the Company’s board of directors
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1725.00 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1725.00 shares
CY2023Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1732500 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1732500 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1957500 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1957500 shares
CY2024Q1 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6000000 shares
CY2023Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
6000000 shares
CY2024Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
each holder of a right will automatically receive one-tenth (1/10) of one ordinary share upon consummation of the initial Business Combination.
CY2024Q1 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
60861367 usd
CY2023Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
60107055 usd

Files In Submission

Name View Source Status
0001493152-24-019972-index-headers.html Edgar Link pending
0001493152-24-019972-index.html Edgar Link pending
0001493152-24-019972.txt Edgar Link pending
0001493152-24-019972-xbrl.zip Edgar Link pending
baya-20240331.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
baya-20240331_cal.xml Edgar Link unprocessable
baya-20240331_def.xml Edgar Link unprocessable
baya-20240331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
baya-20240331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed